Incendia Therapeutics (formerly known as Parthenon Therapeutics) is a biotech company that develops anti-cancer therapies for reprogramming the tumor microenvironment. It focuses on targeting the structural and biochemical underpinnings of tumor microenvironments to enable host immune cells and immuno-oncology therapeutics to reach their target.